Evidence map›Paper›PMID 27163798›Full record

ArticleJournal of Alzheimer's disease : JAD2016

Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.

Michael Happich, Noam Y Kirson, Urvi Desai, Sarah King, Howard G Birnbaum, Catherine Reed, Mark Belger, Alan Lenox-Smith, David Price

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael HappichLilly Deutschland GmbH, Bad Homburg, Germany.
Noam Y KirsonAnalysis Group, Inc., Boston, MA, USA.
Urvi DesaiAnalysis Group, Inc., Boston, MA, USA.
Sarah KingAnalysis Group, Inc., Boston, MA, USA.
Howard G BirnbaumAnalysis Group, Inc., Boston, MA, USA.
Catherine ReedEli Lilly and Company Limited, Windlesham, UK.
Mark BelgerEli Lilly and Company Limited, Windlesham, UK.
Alan Lenox-SmithEli Lilly and Company Limited, Basingstoke, UK.
David PriceResearch in Real Life, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior diagnosis of Alzheimer's disease (AD) among patients later diagnosed with vascular dementia (VaD) has been associated with excess costs, suggesting potential benefits of earlier rule-out of AD diagnosis.

objectiveTo investigate whether prior diagnosis with AD among patients with VaD is associated with excess costs in the UK.

methodsPatients with a final VaD diagnosis, continuous data visibility for≥6 months prior to index date, and linkage to Hospital Episode Statistics data were retrospectively selected from de-identified Clinical Practice Research Datalink data. Patients with AD diagnosis before a final VaD diagnosis were matched to similar patients with no prior AD diagnosis using propensity score methods. Annual excess healthcare costs were calculated for 5 years post-index, stratified by time to final diagnosis.

resultsOf 9,311 patients with VaD, 508 (6%) had prior AD diagnosis with a median time to VaD diagnosis exceeding 2 years from index date. Over the entire follow-up period, patients with prior AD diagnosis had accumulated healthcare costs that were approximately GBP2,000 higher than those for matched counterparts (mostly due to higher hospitalization costs). Cost differentials peaked particularly in the period including the final VaD diagnosis, with excess costs quickly declining thereafter.

conclusionPotential misdiagnosis of AD among UK patients with VaD resulted in substantial excess costs. The decline in excess costs following a final VaD diagnosis suggests potential benefits from earlier rule-out of AD.

Indexed as

Cost of IllnessAgedAged, 80 and overAlzheimer DiseaseCosts and Cost AnalysisDementia, VascularDiagnostic ErrorsFemaleFollow-Up StudiesHealth ResourcesHumansMalePreceptorshipTime FactorsUnited KingdomAlzheimer’s diseasecost and cost analysisdiagnosishealth resourcesvascular dementia

Identifiers

PMID27163798
PMCPMC4942727

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.